The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998) · Science · doi:10.1126/science.279.5350.577 · Cited by 4,490
Two Hundred Gastrointestinal Stromal Tumors: Recurrence Patterns and Prognostic Factors for Survival
DeMatteo, R. P., Lewis, J. J., Leung, D., Mudan, S. S., Woodruff, J. M., & Brennan, M. F. (2000) · Annals of Surgery · doi:10.1097/00000658-200001000-00008 · Cited by 2,554
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301
Verweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.-Y., Issels, R., van Oosterom, A., Hogendoorn, P. C., Van Glabbeke, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17098-0 · Cited by 1,665
Enhanced genome annotation using structural profiles in the program 3D-PSSM 1 1Edited by J. Thornton
Kelley, L. A., MacCallum, R. M., & Sternberg, M. J. E. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3741 · Cited by 1,468
Molecular characterization of the tumor microenvironment in breast cancer
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.010 · Cited by 1,299
Biology of Gastrointestinal Stromal Tumors
Corless, C. L., Fletcher, J. A., & Heinrich, M. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.140 · Cited by 1,224
Cunningham, B. A., Hemperly, J. J., Murray, B. A., Prediger, E. A., Brackenbury, R., & Edelman, G. M. (1987) · Science · doi:10.1126/science.3576199 · Cited by 1,117
The plasminogen activation system in tumor growth, invasion, and metastasis
Andreasen, P. A., Egelund, R., & Petersen, H. H. (2000) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s000180050497 · Cited by 943
Cited by
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Gastrointestinal stromal tumours: origin and molecular oncology
Corless, C. L., Barnett, C. M., & Heinrich, M. C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3143 · Cited by 891
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)00002-x · Cited by 751
The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer
Graham, D. K., DeRyckere, D., Davies, K. D., & Earp, H. S. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3847 · Cited by 698
Lemke, G. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009076 · Cited by 598
“2010), gastrointestinal stromal tumors (Mahadevan et al. 2007), hepatocellularcarcinoma (He et al.”
BackgroundGjerdrum, C., Tiron, C., Høiby, T., Stefansson, I., Haugen, H., Sandal, T., Collett, K., Li, S., McCormack, E., Gjertsen, B. T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909333107 · Cited by 594
“RTKs are a well-established cancer therapeutic class, and small molecule inhibitors ofAxl tyrosine kinase activity have been reported (27, 28).”
BackgroundHolland, S. J., Pan, A., Franci, C., Hu, Y., Chang, B., Li, W., Duan, M., Torneros, A., Yu, J., Heckrodt, T. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2997 · Cited by 550
Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL
Liu, L., Greger, J., Shi, H., Liu, Y., Greshock, J., Annan, R., Halsey, W., Sathe, G. M., Martin, A.-M., & Gilmer, T. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4490 · Cited by 495
“Recent studies report that increased expression of AXL may play a role in resistance to imatinib in gastrointestinal stromal tumors that express cKit (26) and in resistance to chemotherapy in AML (27) as well as in lung (28) and ovarian (29) cancers.”
BackgroundZhu, C., Wei, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1090-3 · Cited by 488
Nguyen, K.-S. H., Kobayashi, S., & Costa, D. B. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.039 · Cited by 437
EGFR-TKIs resistance via EGFR-independent signaling pathways
Liu, Q., Yu, S., Zhao, W., Qin, S., Chu, Q., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0793-1 · Cited by 405
Giving AXL the axe: targeting AXL in human malignancy
Gay, C. M., Balaji, K., & Byers, L. A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.428 · Cited by 334
Molecular chess? Hallmarks of anti-cancer drug resistance
Cree, I. A., & Charlton, P. (2017) · BMC Cancer · doi:10.1186/s12885-016-2999-1 · Cited by 325
Genetics and biomarkers in personalisation of lung cancer treatment
Rosell, R., Bivona, T. G., & Karachaliou, N. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61715-8 · Cited by 305
Rosell, R., Molina, M. A., Costa, C., Simonetti, S., Gimenez-Capitan, A., Bertran-Alamillo, J., Mayo, C., Moran, T., Mendez, P., Cardenal, F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2158 · Cited by 304
“(32) IL-6ST expression leads to gefitinib resistance in EGFR-mutated cell lines, (33) and activation of IGF-1Rb signaling drives gefitinib resistance in EGFR wild-type cancer cell lines.”
BackgroundReceptor Tyrosine Kinase-Targeted Cancer Therapy
Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., & Ohmori, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113491 · Cited by 297
Li, Y., Ye, X., Tan, C., Hongo, J. A., Zha, J., Liu, J., Kallop, D., Ludlam, M. J. C., & Pei, L. (2009) · Oncogene · doi:10.1038/onc.2009.212 · Cited by 288
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Engelman, J. A., & Settleman, J. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.004 · Cited by 284
Zawistowski, J. S., Bevill, S. M., Goulet, D. R., Stuhlmiller, T. J., Beltran, A. S., Olivares-Quintero, J. F., Singh, D., Sciaky, N., Parker, J. S., Rashid, N. U., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0653 · Cited by 180
Arbogast, T., Ouagazzal, A.-M., Chevalier, C., Kopanitsa, M., Afinowi, N., Migliavacca, E., Cowling, B. S., Birling, M.-C., Champy, M.-F., Reymond, A., et al. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1005709 · Cited by 151
Tanaka, H., Sakagami, H., Kaneko, N., Konagai, S., Yamamoto, H., Matsuya, T., Yuri, M., Yamanaka, Y., Mori, M., Takeuchi, M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0976 · Cited by 18
Metadata
- Authors
- Mahadevan, D., Cooke, L., Riley, C., Swart, R., Simons, B., Della Croce, K., Wisner, L., Iorio, M., Shakalya, K., Garewal, H., Nagle, R., & Bearss, D.
- Venue
- Oncogene
- Published
- 2007-02-26
- Volume
- 26
- Issue
- 27
- Pages
- 3909-3919
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2146012957
- Cited by
- 282
- References
- 31
- FWCI
- 11.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.